Distinct Patient, Tumour, Treatment Characteristics and a Different Pattern and Risk of Survival Events Over Time Between Young BRCA1/2 Carriers By Ogkologos - March 10, 2025 695 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a global cohort of patients harbouring germline pathogenic/likely pathogenic variants in BRCA1 or BRCA2 Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Adjuvant Pembrolizumab Improves Overall Survival Among Patients with Clear-Cell Renal Cell... April 24, 2024 Looking to Help Rebuild Strength After Breast Cancer Treatment? Soccer May... April 26, 2021 Dad Gets Tattoo On His Chest To Match Daughter’s Scar So... February 13, 2022 Patients With DCIS Reduce Risk Of Recurrence And Death If They... June 25, 2020 Load more HOT NEWS Alex Trebek Thanks Fans In “Mind-Boggling” Cancer Update. 20 Adorable Tiny Homes That Are Perfect For A Peaceful Weekend... Similarity of Molecular Portraits in Synchronous Bilateral Breast Cancers Could be... How Financial Toxicity Can Impact Cancer Caregivers and Where to Find...